JP2008520705A - ２−メチレン−１９−ノル−１α−ヒドロキシ−１７−エン−ホモプレグナカルシフェロールおよびその使用 - Google Patents

２−メチレン−１９−ノル−１α−ヒドロキシ−１７−エン−ホモプレグナカルシフェロールおよびその使用 Download PDF

Info

Publication number
JP2008520705A
JP2008520705A JP2007543269A JP2007543269A JP2008520705A JP 2008520705 A JP2008520705 A JP 2008520705A JP 2007543269 A JP2007543269 A JP 2007543269A JP 2007543269 A JP2007543269 A JP 2007543269A JP 2008520705 A JP2008520705 A JP 2008520705A
Authority
JP
Japan
Prior art keywords
compound
administered
formula
hydroxy
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007543269A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008520705A5 (https=
Inventor
デルーカ，ヘクター・エフ
タディ，ブルリ・パドマジャ
プラム，ロリ・エイ
クラジェット−ダーム，マーガレット
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wisconsin Alumni Research Foundation
Original Assignee
Wisconsin Alumni Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Research Foundation filed Critical Wisconsin Alumni Research Foundation
Publication of JP2008520705A publication Critical patent/JP2008520705A/ja
Publication of JP2008520705A5 publication Critical patent/JP2008520705A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)
JP2007543269A 2004-11-22 2005-11-18 ２−メチレン−１９−ノル−１α−ヒドロキシ−１７−エン−ホモプレグナカルシフェロールおよびその使用 Pending JP2008520705A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63000704P 2004-11-22 2004-11-22
PCT/US2005/041820 WO2006057901A2 (en) 2004-11-22 2005-11-18 2-METHYLENE-19-NOR-1α-HYDROXY-17-ENE-HOMOPREGNACALCIFEROL AND ITS USES

Publications (2)

Publication Number Publication Date
JP2008520705A true JP2008520705A (ja) 2008-06-19
JP2008520705A5 JP2008520705A5 (https=) 2009-01-15

Family

ID=36216285

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2007543269A Pending JP2008520705A (ja) 2004-11-22 2005-11-18 ２−メチレン−１９−ノル−１α−ヒドロキシ−１７−エン−ホモプレグナカルシフェロールおよびその使用
JP2007543268A Expired - Fee Related JP5161582B2 (ja) 2004-11-22 2005-11-18 １７，２０（ｚ）−デヒドロビタミンｄ類似体およびそれらの使用
JP2007543228A Expired - Fee Related JP5043673B2 (ja) 2004-11-22 2005-11-18 １７，２０（ｅ）−デヒドロビタミンｄ類似体およびそれらの使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2007543268A Expired - Fee Related JP5161582B2 (ja) 2004-11-22 2005-11-18 １７，２０（ｚ）−デヒドロビタミンｄ類似体およびそれらの使用
JP2007543228A Expired - Fee Related JP5043673B2 (ja) 2004-11-22 2005-11-18 １７，２０（ｅ）−デヒドロビタミンｄ類似体およびそれらの使用

Country Status (11)

Country Link
US (6) US7241750B2 (https=)
EP (3) EP1828114B1 (https=)
JP (3) JP2008520705A (https=)
AT (3) ATE465144T1 (https=)
AU (3) AU2005309790B2 (https=)
CA (3) CA2588401C (https=)
DE (3) DE602005021702D1 (https=)
ES (3) ES2346774T3 (https=)
MX (3) MX2007006261A (https=)
NZ (3) NZ555278A (https=)
WO (3) WO2006057885A2 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030188756A1 (en) * 2002-08-19 2003-10-09 Cantorna Margherita T Treatment of inflammatory bowel disease with vitamin d compounds
US8404667B2 (en) 2006-12-29 2013-03-26 Wisconsin Alumni Research Foundation Compounds, compositions, kits and methods of use to orally and topically treat acne and other skin conditions by 19-Nor vitamin D analog
MX2007006261A (es) 2004-11-22 2007-07-10 Wisconsin Alumni Res Found Analogos de 17,20(z)-deshidro vitamina d y sus usos.
DE602005021245D1 (de) * 2004-11-22 2010-06-24 Wisconsin Alumni Res Found 2-methylen-19,26,27-trinor-(20s)-1-alpha-hydroxyvitamin d3 and dessen verwendungen
WO2008091686A2 (en) * 2007-01-25 2008-07-31 Bioxell S.P.A. SYNTHESIS OF 1α-FLUORO-25-HYDROXY-16-23E-DIENE-26,27-BISHOMO-20-EPI-CHOLECALCIFEROL
US7893043B2 (en) * 2008-07-10 2011-02-22 Wisconsin Alumni Research Foundation 2-methylene-(17Z)-17(20)-dehydro-19,21-dinor-vitamin D analogs
US7888339B2 (en) * 2008-07-10 2011-02-15 Wisconsin Alumni Research Foundation 2-methylene-20(21)-dehydro-19-nor-vitamin D analogs
AU2009337184A1 (en) * 2009-01-16 2011-07-28 Anzamed International Limited Medicament for the treatment of pain and inflammation
US20120237472A1 (en) * 2009-07-24 2012-09-20 The Johns Hopkins University Methods and compositions for treating or preventing autoimmune diseases using immunomodulatory agents
EP2525799B1 (en) * 2009-10-02 2014-09-03 Wisconsin Alumni Research Foundation (20s,22e)-2-methylene-19-nor-22-ene-1alpha,25-dihydroxyvitamin d3 analogs
US8664206B2 (en) 2010-03-23 2014-03-04 Wisconsin Alumni Research Foundation Diastereomers of 2-methylene-19-nor-22-methyl-1α,25-dihydroxyvitamin D3
CA2793727C (en) * 2010-03-23 2017-01-03 Wisconsin Alumni Research Foundation Diastereomers of 2-methylene-19-nor-22-methyl-1.alpha.,25-dihydroxyvitamin d3
US8604009B2 (en) * 2010-03-23 2013-12-10 Wisconsin Alumni Research Foundation (20S)-2-methylene-19-nor-22-dimethyl-1α,25-dihydroxyvitamin D3 and (20R)-2-methylene-19-nor-22-dimethyl-1α,25-hydroxyvitamin D3
CA2851283C (en) * 2011-10-21 2020-07-14 Wisconsin Alumni Research Foundation 2-methylene-vitamin d analogs and their uses

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001519327A (ja) * 1997-10-06 2001-10-23 レオ・ファーマシューティカル・プロダクツ・リミテッド・アクティーゼルスカブ （レーベンス・ケミスケ・ファブリック・プロデュクチオンスアクティーゼルスカブ） 新規ビタミンｄ類似体
JP2004512276A (ja) * 2000-09-08 2004-04-22 ウィスコンシン・アルムニ・リサーチ・ファウンデーション １アルファ−ヒドロキシ−２−メチレン−１９−ノル−ホモプレグナカルシフェロール及びその療法的適用
JP2008520704A (ja) * 2004-11-22 2008-06-19 ウィスコンシン・アルムニ・リサーチ・ファウンデーション １７，２０（ｚ）−デヒドロビタミンｄ類似体およびそれらの使用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666634A (en) * 1984-12-05 1987-05-19 Chugai Seiyaku Kabushiki Kaisha vitamin D3 derivatives having a substituent at 2-position
US5145846A (en) 1988-01-20 1992-09-08 Hoffmann-La Roche Inc. Vitamin D3 analogs
GB9004544D0 (en) 1990-03-01 1990-04-25 Leo Pharm Prod Ltd Novel treatment ii
US5362719A (en) 1990-03-01 1994-11-08 Leo Pharmaceutical Products, Ltd. A/S Lovens Kemiske Fabrik Produktionsaktieselskab) Use of vitamin-D analogues in the treatment of acne
ES2070307T3 (es) 1990-07-04 1995-06-01 Marcin Krotkiewski Una preparacion para el tratamiento de la hipertension.
US5086191A (en) * 1991-05-28 1992-02-04 Wisconsin Alumni Research Foundation Intermediates for the synthesis of 19-nor vitamin D compounds
GB9214202D0 (en) * 1992-07-03 1992-08-12 Leo Pharm Prod Ltd Chemical compounds
EP0619306B1 (en) * 1993-04-05 1996-09-11 Wisconsin Alumni Research Foundation 19-Nor-vitamin D3 compounds with substituent at 2-position
US5552392A (en) * 1993-11-03 1996-09-03 Wisconsin Alumni Research Foundation Method of treating hypoparathyroidism with (20S) vitamin D compounds
EP0717034B1 (en) 1994-12-14 1999-04-07 Duphar International Research B.V Vitamin D compounds and method of preparing these compounds
GB9625271D0 (en) * 1996-12-04 1997-01-22 Leo Pharm Prod Ltd Chemical compounds
JP2001511811A (ja) * 1997-02-13 2001-08-14 ボーン ケア インターナショナル インコーポレイテッド ビタミンｄ化合物の標的治療放出
US6316642B1 (en) * 1997-03-17 2001-11-13 Wisconsin Alumni Research Foundation 26,27-Homologated-20-EPI-2alkyl-19-nor-vitamin D compounds
US5843928A (en) * 1997-03-17 1998-12-01 Wisconsin Alumni Research Foundation 2-alkylidene-19-nor-vitamin D compounds
US6392071B1 (en) * 1997-03-17 2002-05-21 Wisconsin Alumni: Research Foundation 26,27-homologated-20-EPI-2-alkylidene-19-nor-vitamin D compounds
US5945410A (en) 1997-03-17 1999-08-31 Wisconsin Alumni Research Foundation 2-alkyl-19-nor-vitamin D compounds
US6306844B1 (en) * 1997-03-17 2001-10-23 Wisconsin Alumni Research Foundation Use of 2α-methyl-19-nor-20(S)-1α, 25-dihydroxyvitamin D3 to increase bone strength
US5936105A (en) * 1997-06-13 1999-08-10 Tetrionics, Inc. 14-EPI-19-nor-vitamin D compounds and methods
KR100593238B1 (ko) 1997-06-25 2006-06-26 데이진 가부시키가이샤 비타민 ｄ3 유도체 및 이로부터 제조된 염증성 호흡기 질환 치료제
WO1999049870A1 (en) * 1998-03-27 1999-10-07 Oregon Health Sciences University Vitamin d and its analogs in the treatment of tumors and other hyperproliferative disorders
NZ522909A (en) * 2000-05-31 2004-09-24 Wisconsin Alumni Res Found 2-ethyl and 2-ethylidene-19-nor-vitamin D compounds
EP1301479A2 (en) * 2000-07-18 2003-04-16 Bone Care International, Inc. STABILIZED 1$g(a)-HYDROXY VITAMIN D
ATE410172T1 (de) 2001-05-22 2008-10-15 Bioxell Spa Verwendung eines analoges des vitamins d3 zur behandlung des autoimmunen diabetes
US6627622B2 (en) * 2002-02-18 2003-09-30 Wisconsin Alumni Research Foundation (20S)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses
US6566352B1 (en) * 2002-02-18 2003-05-20 Wisconsin Alumni Research Foudation 1 α-hydroxy-2-methylene-19-nor-pregnacalciferol and its uses
HK1079766B (zh) * 2002-03-29 2007-05-25 威斯康星校友研究基金会 合成1α-羟基-2-亚甲基-19-去甲-高孕钙化醇的方法
US6846811B2 (en) * 2002-04-22 2005-01-25 Wisconsin Alumni Research Foundation (20S) 1α-hydroxy-2α-methyl and 2β-methyl-19-nor-vitamin D3 and their uses
GB0305332D0 (en) 2003-03-10 2003-04-09 Leuven K U Res & Dev Biological evaluation of novel vitamin D analogues
US20050009792A1 (en) 2003-07-08 2005-01-13 Deluca Hector F. (20S)-1alpha-hydroxy-2-methylene-19-nor-vitamin D3 and its uses
MXPA06005887A (es) 2003-11-25 2006-06-27 Wisconsin Alumni Res Found Analogos de vitamina d para la prevencion y el tratamiento de la obesidad.
EP1694333A2 (en) 2003-11-25 2006-08-30 Deltanoid Pharmaceuticals, Inc. Methods for reducing body fat using vitamin d compounds
AU2005309789A1 (en) 2004-11-22 2006-06-01 Wisconsin Alumni Research Foundation 2alpha-methyl and 2beta-methyl analogs of 19,26,27-trinor-(20S)-1alpha-hydroxyvitamin D3 and their uses
WO2008035207A2 (en) 2006-04-06 2008-03-27 Wisconsin Alumni Research Foundation 2-methylene-1alpha-hydroxy-19,21-dinorvitamin d3 analogs and uses thereof
DK2148684T3 (da) * 2007-04-25 2013-04-22 Cytochroma Inc Fremgangsmåde til behandling af vitamin D-insufficiens og -deficiens

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001519327A (ja) * 1997-10-06 2001-10-23 レオ・ファーマシューティカル・プロダクツ・リミテッド・アクティーゼルスカブ （レーベンス・ケミスケ・ファブリック・プロデュクチオンスアクティーゼルスカブ） 新規ビタミンｄ類似体
JP2004512276A (ja) * 2000-09-08 2004-04-22 ウィスコンシン・アルムニ・リサーチ・ファウンデーション １アルファ−ヒドロキシ−２−メチレン−１９−ノル−ホモプレグナカルシフェロール及びその療法的適用
JP2008520704A (ja) * 2004-11-22 2008-06-19 ウィスコンシン・アルムニ・リサーチ・ファウンデーション １７，２０（ｚ）−デヒドロビタミンｄ類似体およびそれらの使用
JP2008520690A (ja) * 2004-11-22 2008-06-19 ウィスコンシン・アルムニ・リサーチ・ファウンデーション １７，２０（ｅ）−デヒドロビタミンｄ類似体およびそれらの使用

Also Published As

Publication number Publication date
MX2007006262A (es) 2007-07-10
CA2588396A1 (en) 2006-06-01
AU2005309805B2 (en) 2011-06-09
US20070259838A1 (en) 2007-11-08
JP5161582B2 (ja) 2013-03-13
US20060111330A1 (en) 2006-05-25
CA2588396C (en) 2013-04-23
US7241748B2 (en) 2007-07-10
DE602005020842D1 (de) 2010-06-02
EP1828114B1 (en) 2010-04-21
MX2007006546A (es) 2007-08-17
JP2008520704A (ja) 2008-06-19
NZ555277A (en) 2010-12-24
WO2006057885A2 (en) 2006-06-01
US8232263B2 (en) 2012-07-31
US7241750B2 (en) 2007-07-10
ES2344989T3 (es) 2010-09-13
EP1846370A2 (en) 2007-10-24
CA2588410A1 (en) 2006-06-01
DE602005021702D1 (de) 2010-07-15
EP1817279A2 (en) 2007-08-15
WO2006057901A3 (en) 2006-07-13
ATE469883T1 (de) 2010-06-15
AU2005309806B2 (en) 2012-03-08
EP1828114A2 (en) 2007-09-05
WO2006057900A2 (en) 2006-06-01
MX2007006261A (es) 2007-07-10
NZ555282A (en) 2010-12-24
WO2006057885A3 (en) 2006-06-29
ES2346774T3 (es) 2010-10-20
US7241752B2 (en) 2007-07-10
US20070249569A1 (en) 2007-10-25
CA2588410C (en) 2013-04-02
EP1846370B1 (en) 2010-06-02
JP5043673B2 (ja) 2012-10-10
US7741313B2 (en) 2010-06-22
ATE469127T1 (de) 2010-06-15
US20060111321A1 (en) 2006-05-25
WO2006057900A3 (en) 2006-07-06
JP2008520690A (ja) 2008-06-19
US20060116351A1 (en) 2006-06-01
ES2347058T3 (es) 2010-10-25
US7704982B2 (en) 2010-04-27
EP1817279B1 (en) 2010-05-26
NZ555278A (en) 2010-12-24
AU2005309805A1 (en) 2006-06-01
ATE465144T1 (de) 2010-05-15
AU2005309790B2 (en) 2012-03-08
US20070249568A1 (en) 2007-10-25
DE602005021538D1 (de) 2010-07-08
WO2006057901A2 (en) 2006-06-01
CA2588401A1 (en) 2006-06-01
AU2005309806A1 (en) 2006-06-01
CA2588401C (en) 2013-02-12
AU2005309790A1 (en) 2006-06-01

Similar Documents

Publication Publication Date Title
US7704982B2 (en) 2-methylene-19-nor-1α-hydroxy-17-ene-homopregnacalciferol and its uses
US7713952B2 (en) 2-methylene-19,26,27-trinor-(20S)-1α-hydroxyvitamin D3 and its uses
US20060116352A1 (en) 2alpha-Methyl and 2beta-methyl analogs of 19,26,27-trinor-(20S)-1alpha-hydroxyvitamin D3 and their uses
JP2011507966A (ja) ２−メチレン−２０−メチル−１９，２４，２５，２６，２７−ペンタノル−ビタミンｄ類縁体
JP2008520703A (ja) ２α−メチル−１９−ノル−（２０Ｓ）−１α−ヒドロキシ−ビスホモプレグナカルシフェロールおよびその使用
JP5629682B2 (ja) ２−メチレン−（１７ｚ）−１７（２０）−デヒドロ−１９，２１−ジノル−ビタミンｄ類似物質
JP2011527695A (ja) ２−メチレン−１９，２６−ジノル−（２０ｒ，２２ｅ，２５ｒ）−ビタミンｄ類似物質
JP2011527699A (ja) ２−メチレン−１９，２６−ジノル−（２０ｓ，２２ｅ，２５ｒ）−ビタミンｄ類似物質
US8222236B2 (en) 2-methylene-(20E)-20(22)-dehydro-19-nor-vitamin D analogs
JP5043674B2 (ja) ２−メチレン−１８，１９−ジノル−１α−ヒドロキシ−ホモプレグナカルシフェロール及びその使用
JP2011527700A (ja) ２−メチレン−２０（２１）−デヒドロ−１９−ノル−ビタミンｄ類似物質
JP2008538214A (ja) ２−メチレン−１９−ノル−（２３Ｓ）−２５−デヒドロ−１α−ヒドロキシビタミンＤ３−２６，２３−ラクトンおよび２−メチレン−１９−ノル−（２３Ｒ）−２５−デヒドロ−１α−ヒドロキシビタミンＤ３−２６，２３−ラクトン
JP5931845B2 (ja) ２−メチレン−１９−ノル−２２−メチル−１α，２５−ジヒドロキシビタミンＤ３のジアステレオマー

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081118

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20081118

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20110912

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20111102

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111108

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120403